Anthem Biosciences

Anthem Biosciences are an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (“CRDMO”) with fully integrated operations spanning across drug discovery, development and manufacturing with integrated New Chemical Entity (“NCE”) and New Biological Entity (“NBE”) capabilities across drug discovery, development, and commercial manufacturing. We provide end to end CRDMO services and we serve a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally. Anthem Biosciences Limited was originally incorporated as "Anthem Biosciences Private Limited", dated June 13, 2006, issued by RoC. Subsequently, Company was converted from a Private Company to a Public Company , followed by the change in name of the Company to "Anthem Biosciences Limited" and a Certificate of Incorporation was issued by RoC on December 10, 2024. The Company has been set up as a Life sciences/ Biotechnology based venture specialising in the manufacture of catalytic preparation, other organic compounds such as speciality organic molecules, biologically active peptides etc., which are high-value products used in drug, agrochemical and speciality chemicals industries. The Company started operations at Unit I and set up a Custom Synthesis Plant with a capacity of 6 KL in year 2007. It commenced discovery biology services with a fermentation capacity of 2 KL in 2008. It expanded the Custom Synthesis Plant at Unit I increasing its capacity from 6 KL to 24 KL in 2010. It set up a high potent lab at Unit I - Bommasandra Facility in 2016. The Company was merged with Anthem Cellutions (India) Private Limited by acquiring 100% of its share capital in November, 2017. It set up a flow chemistry lab scale and solid phase peptide synthesis GMP lab with a capacity of 6 KL at Unit 1. It commenced operations of the Company at Unit II and set up an automated GMP compliant custom synthesis plant with a capacity of 128 KL and a fermentation plant with a capacity of 80 KL in 2018-19. In year 2020, Company started operations to biological unit 2 earmarked for a specific client. It expanded the custom synthesis plant set up at Unit II increasing its capacity to 246 KL. In FY 2024, Company set up a wholly owned subsidiary Neoanthem Lifesciences Private Limited and commenced operations at Unit III for development in projects. Company launched the initial public offering of 59,575,319 equity shares of face value of Rs 2 each by raising funds through offer for sale aggregating to Rs 3395 Crore in July, 2025. The Company expanded the fermentation capacity to 140 KL at the Unit II in 2025.